Ontology highlight
ABSTRACT:
SUBMITTER: Pal SK
PROVIDER: S-EPMC3253822 | biostudies-literature | 2011 Mar
REPOSITORIES: biostudies-literature
Pal Sumanta Kumar SK Figlin Robert A RA
Targeted oncology 20110301 1
With an explosion of available treatments for metastatic renal cell carcinoma (mRCC) in recent years, it is important to recognize that approved targeted therapies fall broadly into only two mechanistic categories. The first category, vascular endothelial growth factor (VEGF)-directed therapies, includes sunitinib, pazopanib, sorafenib and bevacizumab. The second category includes inhibitors of the mammalian target of rapamycin (mTOR), namely everolimus and temsirolimus. A pivotal trial of evero ...[more]